AVXL — Anavex Life Sciences Income Statement
0.000.00%
Last trade - 00:00- $771.33m
- $670.16m
- 37
- 17
- 78
- 39
Annual income statement for Anavex Life Sciences, fiscal year end - September 30th, USD millions except per share, conversion factor applied.
2020 September 30th | 2021 September 30th | 2022 September 30th | 2023 September 30th | 2024 September 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 31.1 | 42 | 51 | 55.8 | 52.9 |
| Operating Profit | -31.1 | -42 | -51 | -55.8 | -52.9 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -26.3 | -37.6 | -47.6 | -47.5 | -43 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -26.3 | -37.9 | -48 | -47.5 | -43 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -26.3 | -37.9 | -48 | -47.5 | -43 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -26.3 | -37.9 | -48 | -47.5 | -43 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.452 | -0.543 | -0.624 | -0.595 | -0.515 |